October 30, 2006Open Access
Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group
Key Points
Key points are not available for this paper at this time.
Abstract
Adding docetaxel to CF significantly improved TTP, survival, and response rate in gastric cancer patients, but resulted in some increase in toxicity. Incorporation of docetaxel, as in DCF or with other active drug(s), is a new therapy option for patients with untreated advanced gastric cancer.
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Authors
Eric Van Cutsem
KU Leuven
V
Vladimir Moiseyenko
State Budget Institution of Health St. Petersburg Clinical Research Center Specialized Types of Medical Care
S
Sergei Tjulandin
Georgetown University
Journals
Journal of Clinical Oncology
Actions
Institutions
Hospitais da Universidade de Coimbra
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...